MX2015007147A - Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab. - Google Patents

Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.

Info

Publication number
MX2015007147A
MX2015007147A MX2015007147A MX2015007147A MX2015007147A MX 2015007147 A MX2015007147 A MX 2015007147A MX 2015007147 A MX2015007147 A MX 2015007147A MX 2015007147 A MX2015007147 A MX 2015007147A MX 2015007147 A MX2015007147 A MX 2015007147A
Authority
MX
Mexico
Prior art keywords
amyloid plaques
antibody
antigen
binding fragment
antibodies
Prior art date
Application number
MX2015007147A
Other languages
English (en)
Inventor
Thomas Engber
Thierry Bussiere
Paul H Weinreb
Kenneth Rhodes
Joseph Arndt
Fang Qian
Robert W Dunstan
Shailendra Patel
Jan Grimm
Marcel Maier
Original Assignee
Biogen Internat Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Internat Neuroscience Gmbh filed Critical Biogen Internat Neuroscience Gmbh
Publication of MX2015007147A publication Critical patent/MX2015007147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con el uso del anticuerpo anti-AB o fragmento de unión al antígeno de este para reducir placas amiloides cerebrales, o minimizar la aparición de microhemorragia durante la dosificación crónica de un anticuerpo anti-Ab o fragmento de unión al antígeno de este. Por ejemplo, la descripción se relaciona con el método de reducción de placas amiloides cerebrales, que comprende administrar a un sujeto un anticuerpo anti-AB o un fragmento de unión al antígeno de este que se une al mismo epítopo que el anticuerpo BIIB037, donde la administración puede reducir las placas amiloides en el cerebro sin afectar el amiloide vascular, y donde el anticuerpo BIIB037 se une a un epítopo que comprende los aminoácidos 3-6 de AB.
MX2015007147A 2012-12-07 2013-12-06 Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab. MX2015007147A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734799P 2012-12-07 2012-12-07
US201361773794P 2013-03-06 2013-03-06
PCT/US2013/073700 WO2014089500A1 (en) 2012-12-07 2013-12-06 A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2015007147A true MX2015007147A (es) 2016-07-26

Family

ID=50884049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007147A MX2015007147A (es) 2012-12-07 2013-12-06 Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.

Country Status (13)

Country Link
US (1) US20150315267A1 (es)
EP (1) EP2928494A4 (es)
JP (1) JP2016501247A (es)
KR (1) KR20150127570A (es)
CN (1) CN105979962A (es)
AU (1) AU2013354968A1 (es)
BR (1) BR112015013312A2 (es)
CA (1) CA2894178A1 (es)
EA (1) EA201591019A1 (es)
HK (1) HK1215673A1 (es)
IL (1) IL239259A0 (es)
MX (1) MX2015007147A (es)
WO (1) WO2014089500A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN105616405B (zh) * 2014-11-05 2021-05-07 中国人民解放军第三军医大学第三附属医院 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
TWI800009B (zh) * 2015-07-15 2023-04-21 美商蓋斯特維炫股份有限公司 用於檢測折疊錯誤蛋白質之裝置及其使用方法
WO2017013599A1 (en) * 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
EP4316512A3 (en) 2015-10-28 2024-04-24 The Trustees of The University of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3026598A1 (en) * 2016-06-07 2017-12-14 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
JP7210612B2 (ja) 2018-05-30 2023-01-23 ナショナル ヘルス リサーチ インスティチューツ 抗ａベータ抗体及びその使用
WO2021108861A1 (en) * 2019-12-03 2021-06-10 The University Of Queensland Treatment of neurodegenerative diseases using ultrasound and amyloid-beta antibodies
EP4185612A1 (en) 2020-07-23 2023-05-31 Othair Prothena Limited Anti-abeta antibodies
WO2023180811A2 (en) 2022-03-22 2023-09-28 Insightec Ltd. Monitoring tissue permeability during ultrasound procedures
WO2024157085A1 (en) 2023-01-26 2024-08-02 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies
WO2024209347A1 (en) 2023-04-02 2024-10-10 Insightec Ltd. Control of ultrasound procedures by monitoring microbubble response

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
EP2321348A2 (en) * 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
ITRM20120383A1 (it) * 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.

Also Published As

Publication number Publication date
US20150315267A1 (en) 2015-11-05
EP2928494A1 (en) 2015-10-14
CA2894178A1 (en) 2014-06-12
WO2014089500A1 (en) 2014-06-12
CN105979962A (zh) 2016-09-28
EP2928494A4 (en) 2016-11-02
HK1215673A1 (zh) 2016-09-09
EA201591019A1 (ru) 2015-11-30
KR20150127570A (ko) 2015-11-17
IL239259A0 (en) 2015-07-30
JP2016501247A (ja) 2016-01-18
AU2013354968A1 (en) 2015-07-16
BR112015013312A2 (pt) 2017-11-14

Similar Documents

Publication Publication Date Title
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
MX2023010900A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo.
PH12016501120A1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
EA201491006A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
WO2014160133A3 (en) Anti-(+) --methamphetamine monoclonal antibodies
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders